| Total 939 Paclitaxel
related US patents (from
US Patent & Trademark Office)
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 400 / 401 - 500
/ 501 - 600 / 601
- 700 / 701 - 800
/ 801
- 900 / 901 -939
/
No. 401 - 500 Paclitaxel Patents:
|
PAT. NO. |
|
Title |
| 401 |
6,307,071 |
 |
Synthesis
of paclitaxel from baccatin III by protection of the 7-hydroxyl of
baccatin III using a strong base and an electrophile |
| 402 |
6,306,993 |
|
Method
and composition for enhancing transport across biological
membranes |
| 403 |
6,306,894 |
|
Injectable
composition |
| 404 |
6,306,893 |
|
Taxoid
derivatives and process for producing the same |
| 405 |
6,306,874 |
|
Tyrosine
kinase inhibitors |
| 406 |
6,306,423 |
|
Neurotoxin
implant |
| 407 |
6,306,421 |
|
Therapeutic
inhibitor of vascular smooth muscle cells |
| 408 |
6,306,403 |
|
Method
for treating parkinson's disease with a botulinum toxin |
| 409 |
6,306,166 |
|
Loading
and release of water-insoluble drugs |
| 410 |
6,303,584 |
|
Water
soluble lipidated arabinogalactan |
| 411 |
6,303,569 |
|
Trialkyl-lock-facilitated
polymeric prodrugs of amino-containing bioactive agents |
| 412 |
6,303,342 |
|
Recombinant
methods and materials for producing epothilones C and D |
| 413 |
6,302,838 |
|
Cancer
treatment with epothilones |
| 414 |
RE37,410 |
|
Controlled
local delivery of chemotherapeutic agents for treating solid
tumors |
| 415 |
6,300,355 |
|
Synthesis
of epothilones, intermediates thereto, analogues and uses thereof |
| 416 |
6,299,869 |
|
Human
interferon-epsilon: a type I interferon |
| 417 |
6,299,604 |
|
Coated
implantable medical device |
| 418 |
6,297,337 |
|
Bioadhesive
polymer compositions |
| 419 |
6,297,272 |
|
Artemisinin
analogs having antimalarial antiproliferative and antitumor
activities and chemoselective methods of making the same |
| 420 |
6,297,239 |
|
Inhibitors
of prenyl-protein transferase |
| 421 |
6,297,230 |
|
Cyanoaziridines
for treating cancer |
| 422 |
6,296,870 |
|
Liposomes
containing active agents |
| 423 |
6,296,833 |
|
Human
calcium-sensing receptor in the detection and treatment of cancer |
| 424 |
6,294,695 |
|
Aminobenzoic
acid derivatives having anti-tumorigenic activity methods of
making and using the same |
| 425 |
6,294,546 |
|
Uses
of diterpenoid triepoxides as an anti-proliferative agent |
| 426 |
6,294,192 |
|
Triglyceride-free
compositions and methods for improved delivery of hydrophobic
therapeutic agents |
| 427 |
6,291,690 |
|
Hydrophobic
taxane derivatives |
| 428 |
6,291,684 |
|
Process
for the preparation of aziridinyl epothilones from oxiranyl
epothilones |
| 429 |
6,291,504 |
|
Acylsemicarbazides
and their uses |
| 430 |
6,291,496 |
|
Treating
cancers associated with overexpression of class I family of
receptor tyrosine kinases |
| 431 |
6,291,425 |
|
Compounds,
methods and pharmaceutical compositions for treating cellular
damage, such as neural or cardiovascular tissue damage |
| 432 |
6,290,929 |
|
Cancer
treatment |
| 433 |
6,288,237 |
|
Epothilons
C and D, preparation and compositions |
| 434 |
6,288,046 |
|
Phosphonic
acid derivatives |
| 435 |
6,288,040 |
|
Medicament
excipient particles for tissue-specific application of a
medicament |
| 436 |
6,288,039 |
|
Pharmaceutical
compositions methods and kits for treatment and diagnosis of
breast cancer |
| 437 |
6,287,835 |
|
Transacylases
of the paclitaxel biosynthetic pathway |
| 438 |
6,287,628 |
|
Porous
prosthesis and a method of depositing substances into the pores |
| 439 |
6,287,602 |
|
Treatment
of oncologic tumors with an injectable formulation of a Golgi
apparatus disturbing agent |
| 440 |
6,287,588 |
|
Agent
delivering system comprised of microparticle and biodegradable gel
with an improved releasing profile and methods of use thereof |
| 441 |
6,287,285 |
|
Therapeutic,
diagnostic, or hydrophilic coating for an intracorporeal medical
device |
| 442 |
6,284,923 |
|
Substituted
benzene compounds as antiproliferative and cholesterol lowering
action |
| 443 |
6,284,781 |
|
Synthesis
of epothilones, intermediates thereto, analogues and uses thereof |
| 444 |
6,284,755 |
|
Inhibitors
of prenyl-protein transferase |
| 445 |
6,284,746 |
|
Inclusion
complexes of taxol or taxotere or taxus extract formed with
cyclodextrins, its preparation and use |
| 446 |
6,284,268 |
|
Pharmaceutical
compositions containing an omega-3 fatty acid oil |
| 447 |
6,284,267 |
|
Amphiphilic
materials and liposome formulations thereof |
| 448 |
6,281,368 |
|
Simple
and efficient hydrazinolysis of C-10 and C-13 ester
functionalities of taxanes to obtain 10-DAB III |
| 449 |
6,281,223 |
|
Radioenhanced
camptothecin derivative cancer treatments |
| 450 |
6,281,175 |
|
Medical
emulsion for lubrication and delivery of drugs |
| 451 |
6,280,981 |
 |
Compositions
and methods for assaying subcellular conditions and processes using
energy transfer |
| 452 |
6,280,966 |
|
Indicators
of altered mitochondrial function in predictive methods for
determining risk of type 2 diabetes mellitus |
| 453 |
6,280,411 |
|
Localized
delivery of drug agents |
| 454 |
6,277,844 |
|
Compound
for selective treatment of malignant cells by inhibiting cell cycle
progression, decreasing Bcl2, and increasing apoptosis |
| 455 |
6,277,413 |
|
Biodegradable
compositions for the controlled release of encapsulated substances |
| 456 |
6,277,410 |
|
Copolymer
compositions for oral delivery |
| 457 |
6,277,391 |
|
Composition
and method of treating diseases and disorders of the prostate |
| 458 |
6,274,635 |
|
Alkylated
resorcinol derivatives for the treatment of immune diseases |
| 459 |
6,271,245 |
|
Hydroxamic
acid derivatives |
| 460 |
6,271,217 |
|
Method
of treating cancer with a benzimidazole and a chemotherapeutic agent |
| 461 |
6,271,196 |
|
Methods
of alleviating neuropathic pain using prosaposin-derived peptides |
| 462 |
6,268,488 |
|
Prodrug
activation using catalytic antibodies |
| 463 |
6,268,398 |
|
Compounds
and methods for treating mitochondria-associated diseases |
| 464 |
6,268,347 |
|
Prosaposin-derived
peptides |
| 465 |
6,268,334 |
|
Peptide
antagonists of DP transcription factors |
| 466 |
6,267,985 |
|
Clear
oil-containing pharmaceutical compositions |
| 467 |
6,267,957 |
|
Attaching
agents to tissue with transglutaminase and a transglutaminase
substrate |
| 468 |
6,265,609 |
|
Thio-substituted
pentanedioic acid derivatives |
| 469 |
6,265,587 |
|
Intermediary
compounds for the hemisynthesis of taxanes and preparation processes
therefor |
| 470 |
6,265,427 |
|
Pharmaceutical
composition for the method of treating leukemia |
| 471 |
6,265,385 |
|
Topoisomerase
II poison and bis-dioxopiperazine derivative combination therapy |
| 472 |
6,262,281 |
|
Syntheses
of taxol, taxol analogs and their intermediates with variable A-ring
side chain structures and compositions thereof |
| 473 |
6,262,116 |
|
Transcription
therapy for cancers |
| 474 |
6,262,107 |
|
Water
soluble paclitaxel prodrugs |
| 475 |
6,262,096 |
|
Aminothiazole
inhibitors of cyclin dependent kinases |
| 476 |
6,262,094 |
|
C-21
modified epothilones |
| 477 |
6,262,054 |
|
Combination
therapy method for treating breast cancer using edatrexate |
| 478 |
6,262,032 |
|
Method
of destroying hyperproliferative cells by combined p53 and taxoid
treatment |
| 479 |
6,261,813 |
|
Two
step enzymatic acylation |
| 480 |
6,261,795 |
|
Radiation
resistance assay for predicting treatment response and clinical
outcome |
| 481 |
6,261,760 |
|
Regulation
of the cell cycle by sterols |
| 482 |
6,258,841 |
|
Tubulin
binding compounds (COBRA) |
| 483 |
6,258,796 |
|
Water
soluble lipidated arabinogalactan |
| 484 |
6,258,121 |
|
Stent
coating |
| 485 |
6,255,540 |
|
Methods
for producing two-substituted glycerols having various levels of
protection |
| 486 |
6,255,479 |
|
Process
for the preparation of .alpha.-oxolactams |
| 487 |
6,255,347 |
|
Methods
and compositions comprising R-ibuprofen |
| 488 |
6,254,632 |
|
Implantable
medical device having protruding surface structures for drug
delivery and cover attachment |
| 489 |
6,252,050 |
|
Method
for making monoclonal antibodies and cross-reactive antibodies
obtainable by the method |
| 490 |
6,251,870 |
|
Pharmaceutical
composition for inhibiting growth of cancers |
| 491 |
6,251,682 |
|
Method
and markers for prognosticating efficacy of anticancer agents |
| 492 |
6,251,428 |
|
Preparation
of aqueous clear solution dosage forms with bile acids |
| 493 |
6,251,382 |
|
Biodegradable
high molecular weight polymeric linkers and their conjugates |
| 494 |
6,248,908 |
|
Process
for the preparation of a paclitaxel C-4 methyl carbonate analog |
| 495 |
6,248,776 |
|
Anti-first-pass
effect compounds |
| 496 |
6,248,752 |
|
Azabicyclooctane
compositions and methods for enhancing chemotherapy |
| 497 |
6,248,363 |
|
Solid
carriers for improved delivery of active ingredients in
pharmaceutical compositions |
| 498 |
6,248,057 |
|
Absorbable
brachytherapy and chemotherapy delivery devices and methods |
| 499 |
6,245,805 |
|
Method,
compositions and kits for increasing the oral bioavailability of
pharmaceutical agents |
| 500 |
6,245,759 |
|
Tyrosine
kinase inhibitors |
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 400 / 401 - 500
/ 501 - 600 / 601
- 700 / 701 - 800
/ 801
- 900 / 901 -939
/
|
